G&E Herbal Biotechnology Co., Ltd. (TPEX:4911)

G&E Herbal Biotechnology Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	102.06	72.4	7.38	-19.88	-14.3
Depreciation & Amortization	10.38	9.33	9.4	9.33	9.21
Other Amortization	-	-	-	0	0
Loss (Gain) From Sale of Assets	0.01	0.01	0	0.02	0.01
Other Operating Activities	22.5	17.98	0.71	1.67	-2.51
Change in Accounts Receivable	-3.04	-14.19	4.38	1.08	-2.22
Change in Inventory	1.2	1.74	-5.69	-2.85	0.14
Change in Accounts Payable	1.42	-2	2.47	-0.35	0.35
Change in Unearned Revenue	-10.01	23.39	71.39	0.28	0
Change in Other Net Operating Assets	10.16	4.82	9.92	1.52	10.09
Operating Cash Flow	134.68	113.48	99.96	-9.19	0.77
Operating Cash Flow Growth	18.68%	13.52%	-	-	-
Capital Expenditures	-5.92	-5.52	-2.95	-1.77	-5
Sale (Purchase) of Intangibles	-0.08	-	-0.01	-0.22	-1.77
Investment in Securities	-83.05	-82.04	5.4	9	15.9
Other Investing Activities	-0.19	-0.87	0.07	-	-0.01
Investing Cash Flow	-89.24	-88.43	2.51	7.01	9.13
Long-Term Debt Repaid	-0.77	-0.12	-	-	-
Net Debt Issued (Repaid)	-0.77	-0.12	-	-	-
Common Dividends Paid	-31.76	-	-	-	-
Financing Cash Flow	-32.54	-0.12	-	-	-
Net Cash Flow	12.9	24.94	102.47	-2.18	9.9
Free Cash Flow	128.76	107.96	97.01	-10.96	-4.23
Free Cash Flow Growth	19.26%	11.29%	-	-	-
Free Cash Flow Margin	51.70%	59.50%	150.15%	-44.61%	-14.98%
Free Cash Flow Per Share	2.18	1.83	1.64	-0.19	-0.07
Cash Interest Paid	0.04	0	-	-	-
Cash Income Tax Paid	0.15	0.02	-	-	-
Levered Free Cash Flow	82.35	67.88	93.19	-5.52	-7.17
Unlevered Free Cash Flow	82.37	67.88	93.19	-5.52	-7.17
Change in Net Working Capital	-3.22	-13.64	-83.33	0.64	-0.05

Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.